DiagnosticLaunch & access18 Sept 2026Part two of two

The door opens twice a year

Southeast Asia now registers on reliance, in ninety working days or less in several markets. Then the product waits for a committee that meets three times a year, or twice, or which in Vietnam's case has not substantively met since 2018.

Who this is for

Country and regional managers, market access and launch teams working across Southeast Asia. Most useful if you are setting a launch date, building a year one forecast, or planning entry into Indonesia or Vietnam.

Anita Menon

Commercial leadership across the GCC, India and APAC

Part one said the Gulf got fast at registration and stayed slow at buying. Southeast Asia is the same shape with different machinery, which is why a team that has learned one region walks into the other and gets it wrong.

The regulatory side is quick. Singapore sits at WHO Maturity Level 4, same tier as Saudi Arabia, and became a WHO Listed Authority in 2023. Its verification route runs 110 working days end to end. Indonesia's fast route runs 90. Vietnam's, in law since July 2025, runs nine months against twelve for the standard route. Malaysia opened a sixty-day pilot in May 2026.

Every one of those needs an approval someone else granted first. And in none of these markets is the regulator what holds you up. A committee with a calendar is.

The calendar is the constraintHow often each market's reimbursement gate opens. Singapore's drug advisory committee meets three to four times a year and publishes its dates. Malaysia's formulary panel has historically met three times a year, on a schedule last published in an earlier edition of its guidelines. Thailand's essential medicines list and Indonesia's national formulary are refreshed roughly every two years. Vietnam's reimbursement list has had no substantive refresh since 2018. Derived from published calendars and regulations, not from measured outcomes.

Registration timelines are measured in working days. The gate is measured in years.

Five questions follow. They are the Southeast Asian versions of the five in part one, and the answers cost different things.

The diagnostic

Five questions, in this order

Which committee meeting are you aiming at, and when does it sit?

A date, not a half-year.

If the answer is a half-year Singapore publishes its calendar far enough ahead that the date is calculable: for the March 2027 committee, intent was due in March 2026 and evidence in September 2026. Malaysia's panel has historically sat three times a year, with a cut-off before each, though the current schedule should be confirmed with the ministry. Thailand and Indonesia refresh roughly every two years. Missing a meeting does not cost weeks.

Is your reliance window still open?

Check the reference approval date, not your filing date.

If nobody has checked Malaysia's recognition pilot requires submission within three months of FDA or EMA approval, the tightest window in the region. Singapore's verification route requires two reference approvals with the primary inside three years. Indonesia's requires approval inside five. These clocks start on someone else's decision, so a plan that sequences Asia behind the EU5 may find the fast route already closed.

In Indonesia and Vietnam, what is the second gate?

Listing is not buying. Name the procurement step.

If the plan stops at the formulary Indonesia lists on the national formulary, and the product then still has to reach the health ministry's electronic catalogue before an institution can buy it. That catalogue has been mid-migration between platforms, so its current operating state is worth confirming directly rather than assuming. Vietnam sorts generics into five technical tiers that set both the achievable price and who you are bidding against. Two gates, not one, and the second is where volume and price are actually decided.

What is your Vietnam reimbursement assumption?

Ask what year the list was last substantively refreshed.

If nobody knows, it is 2018 A draft adding 84 medicines, including 30 in oncology, went out for comment in November 2025 and was still unissued in March 2026. For a product registered after 2018 and not on the list, the honest planning assumption is that reimbursement is not a near-term event, whatever the nine-month registration route suggests.

Where does each market sit on the localisation ladder?

Preference, requirement and exclusion are three different things.

If they are being treated as one thing Indonesia's 2026 health supplies regulation requires imported medicines to be produced domestically within five years, and its local content formula weights the active ingredient at half the score, so importing the ingredient and formulating locally caps you structurally. Vietnam goes furthest: an April 2024 circular named 93 medicines for which an imported product may not be offered at all, and a replacement list has been in draft, so assume it has grown. The Philippines' 2024 procurement act obliges public buyers to award to domestic bidders for a ten-year period, though whether medicines fall inside its covered product list is worth checking before you plan on it.

Reading the pattern

Fail on one or two and you have lost a year to a calendar. That is recoverable once and expensive twice.

Fail on three and you will report a formulary listing as an access win, then spend two quarters explaining why the volume did not follow.

Fail on four and your Vietnam number is fiction, and it is usually a number somebody has already committed to.

Fail on five and you are on the wrong side of a ladder that is still being climbed. A preference you can price. A requirement you must plan for. An exclusion you cannot bid against.

What the two regions share

Both got faster at registration, and in both the speed is reliance speed. Every expedited route in the Gulf and in Southeast Asia is conditioned on a prior FDA or EMA approval, which means neither region has moved ahead of the United States, and neither is structured to. The consultancy claim that these are becoming first-wave markets does not survive contact with the eligibility rules.

In both, the binding constraint moved to the back end, and the back end did not get faster. What differs is what the back end is made of. In the Gulf it is a tender calendar you can read and a price preference you can put a number on, up to thirty per cent. In Southeast Asia it is a committee calendar, a second procurement gate behind the first in two markets, and a localisation regime that in places is no longer a preference at all.

Preference. Requirement. Exclusion. The ladder has moved a rung in two years.

The planning implication is the same in both regions. A launch model that treats registration as the milestone is measuring the part of the system that improved and ignoring the part that did not. The question that predicts revenue is not when you will be approved. It is which meeting you are aiming at, and what you will be allowed to bid.

On sources

Named, dated sources throughout: Singapore's Health Sciences Authority turnaround schedules and the Agency for Care Effectiveness procedures and published committee calendar; Malaysia's drug registration guidance and facilitated registration pathway, and the health ministry formulary guidelines; Thailand's public service process register and the national essential medicines list announcements; Indonesia's BPOM Regulation 23 of 2025 and health ministry regulation 5 of 2026; Vietnam's Law 44 of 2024 and Circulars 12 of 2025, 07 of 2024, 40 of 2025 and 03 of 2024; Philippine FDA circulars, the 2024 procurement act and the Health Technology Assessment Council's annual report; World Health Organization maturity and listed authority registers.

Limits worth stating rather than burying. No published median exists for the lag from registration to reimbursement in any of these six markets, so the figures here are derived from published calendars and cycles rather than measured outcomes. Thailand's reliance timeline for medicines could not be confirmed from the Thai FDA itself. Malaysia's three-meeting cycle comes from an earlier edition of its formulary guidelines; the current edition was not retrievable. Vietnam's nine-month reliance route is reported consistently by independent legal and trade sources but was not read from the statute. Whether Vietnam's 84-medicine draft has been issued since March 2026, whether its 93-medicine exclusion list has grown, whether Indonesia's electronic catalogue migration has completed, and whether medicines sit inside the Philippine covered product list are all open questions that a call to an affiliate would settle faster than a search will.

One page

Take it into the room

The same five questions on a single A4 sheet, sized to print and hand across a table.

Download the PDF →

Run it and tell me what you found

If your launch model dates revenue from registration in either region, that is the kind of thing I am useful for.

Tell me what needs to change →